Pharmadrug, Inc.

As of June 30, 2026, Pharmadrug, Inc. has 134.21M shares outstanding.

As of June 30, 2026, Pharmadrug, Inc. maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -99.81, indicating conservative leverage, while an interest coverage ratio of -0.44 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -96.36, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Pharmadrug, Inc.'s stock has declined approximately 96.43% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

Over the twelve months ended June 30, 2026, Pharmadrug, Inc. generated - - in revenue and converted that into -395,404.37 in net income, yielding earnings per share of 0.00. EBITDA reached -107,333.89, while operating income came in at -138,321.96.

As of June 30, 2026, Pharmadrug, Inc. holds 14,222.29 in cash and equivalents against 1.05M in total debt, resulting in a net debt position of 1.04M. Total book value stands at -1.11M, with working capital of -1.31M providing operational flexibility.

Pharmadrug, Inc. produced -55,234.42 in operating cash flow over the twelve months ended June 30, 2026.

Pharmadrug, Inc.'s most recent stock split took place on October 24, 2023 with a 7:1 split ratio.